There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Akt1


Akt1 Molecule Information

Name:Serine/threonine-protein kinase AKT
Target Synonym:RAC-alpha serine/threonine-protein kinase;RAC-PK-alpha;PKB alpha;PKB;Protein kinase B alpha;Proto-oncogene c-Akt;PKB ;AKT1;Protein kinase B;RAC
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Phase ?

Akt1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AK1-H5283 Human Human Akt1 Protein, His,Strep II Tag

Akt1 Molecule Synonym Name

AKT1,PKB,RAC,RAC-PK-alpha,PKB alpha

Akt1 Molecule Background

RAC-alpha serine/threonine-protein kinase (AKT1) is also known PKB, Protein kinase B alpha, PKB alpha, Proto-oncogene c-Akt and RAC-PK-alpha, which belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family and RAC subfamily and is expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase).

Akt1 References

Akt1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Miransertib ARQ-092 Phase Ⅱ ArQule Growth failure, Proteus Syndrome (PS) Details
Uprosertib GSK-2141795; GSK-2141795C; GSK-795 Phase Ⅱ National Cancer Institute, GlaxoSmithKline, Novartis, Laekna Therapeutics Endometrial cancer, Breast cancer, Multiple myeloma (MM), Acute myeloid Leukemia (AML), Cervical carcinoma, Melanoma Details
SR-0379 SR-0379,SR0379 Preclinical FunPep, Shionogi Skin ulcer Details
Oxysterols (Intsel Chimos) Phase Not Specified Centre National de la Recherche Scientifique (CNRS), Intsel Chimos Glioma Details
Selumetinib Sulfate/MK-2206 Phase Ⅱ Merck Sharp & Dohme, AstraZeneca Acute lymphoblastic leukaemia (ALL) Details
Honokiol HU-002 Phase Ⅲ Anacor Pharmaceuticals, Colgate Palmolive Gingival diseases Details
Ipatasertib Dihydrochloride GDC-0068; RG-7440; GCD-0068 Phase Ⅲ Array BioPharma, Roche Prostate cancer, Breast cancer Details
MSC-2363318A MSC-2363318A; M-2698,MSC2363318A,M2698 Phase Ⅰ Merck Serono Solid tumours Details
Uprosertib/Trametinib Dimethyl Sulfoxide Phase Ⅱ Novartis Endometrial cancer, Acute myeloid Leukemia (AML), Cervical carcinoma Details
Triciribine Phosphate VQD-002; VQD-002-ORAL; NSC-154020; API-2; TCN-P; PTX-002; NSC-280594 Phase Ⅱ National Cancer Institute, VioQuest, Prescient Breast cancer, Acute myeloid Leukemia (AML), Ovarian cancer Details
MK-8156 MK-8156 Phase Ⅰ Merck Sharp & Dohme Cancer Details
CLR-131 (131)I-NM 404; CLR-131; CLR1404 I-131; HOT; NM404; I-131-CLR1404; (131)I-CLR1404; 131I-NM-404 ,CLR131,I131CLR1404 Phase Ⅱ University of Michigan, Cellectar Non small cell lung cancer (NSCLC), Solid tumours, Multiple myeloma (MM) Details
BAY-1125976 BAY-1125976,BAY1125976 Phase Ⅰ Bayer Solid tumours Details
CMX-2043 CMX-2043; LIP-EA; R-LIP-EA-OH,CMX2043,LIPEA,RLIPEAOH Phase Ⅱ Ischemix Ischemia-reperfusion injury Details
HZB0071 HZB-0071 Phase Ⅰ WuXi AppTec, ZBD Pharmaceutical Cancer Details
Palomids P-52901; P-529; Palomid-529; RES-529; SG-00529,SG00529,RES529,Palomid529 Phase Ⅰ Diffusion Pharmaceuticals Age-related macular degeneration (AMD) Details
SR-13668 SR-13668,SR13668 Phase Ⅰ Bridge, National Cancer Institute, SRI International Solid tumours, Lymphoma Details
MK-2206 MK-2206; MK2206; BIND-2206; NSC-749607 Phase Ⅱ Merck Sharp & Dohme Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer Details
Capivasertib AZD-5363 Phase Ⅲ AstraZeneca Breast cancer Details
AT-13148 AT-13148,AT13148 Phase Ⅰ Astex Pharmaceuticals Solid tumours Details
GSK-690693 GSK-690693,GSK690693 Phase Ⅰ GlaxoSmithKline Solid tumours, Lymphoma Details
Afuresertib ASB-183; GSK-2110183; GSK-2110183C; GSK-21110183; GSK-2110183B Phase Ⅱ GlaxoSmithKline, Novartis, Laekna Therapeutics Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM), Ovarian cancer Details
CLR-124 CLR-124; CLR-1404-[124I]; NM-404-[124I]; [124I]CLR-1404; [124I]NM-404 Phase Ⅱ University of Michigan, Cellectar Diagnostic agents Details
RX-0301 RX-0301; RX-0201; RX-0201 Nano; RX-0201 nanoliposomal; RX-0201-N Phase Ⅱ Rexahn Pharmaceuticals, Zhejiang Haichang Biomedical, Rexgene Renal carcinoma, Pancreatic cancer Details
XL-418 XL-418; EXEL-9418,XL418 Phase Ⅰ Exelixis Solid tumours Details
TIC-10 ONC201 - Oncoceutics; TIC-10; ONC-201; NSC-350625; ONC201/TIC10 Phase Ⅱ Oncoceutics Neuroendocrine tumors (NET), Glioma, Endometrial cancer, Breast cancer, Glioblastoma Details
TAS-117 TAS-117,TAS117 Phase Ⅱ Otsuka, Taiho Pharma Solid tumours Details

This web search service is supported by Google Inc.